DHR - DHR ダナハ― （）

In this article, we take a look at the 5 safe stocks to buy according to hedge funds. If you want to read our detailed analysis of safe stocks, go directly to see the 12 Safe Stocks to Buy According to Hedge Funds. 5. Danaher Corporation (NYSE:DHR) Beta Value: 0.82 Number of Hedge Fund Holders: 89 […]

Life sciences company Danaher Corporation (DHR) has expressed interest in buying the contract manufacturer Catalent (CTLT), people familiar with the matter said. Read the full story here.

Medical equipment maker Danaher Corp has expressed interest in taking over contract drugmaker Catalent Inc , Bloomberg News reported on Saturday, citing people familiar with the matter.

Related Stocks: G , DHR , ADI , ACI , AGR ,

Related Stocks: DHR , AVGOP.PFD , CHRD , ACWX , AVGO ,

Pune, July 07, 2022 (GLOBE NEWSWIRE) -- Genomics Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service, organization size, end-use verticals, and Region – Global Genomics Market Forecast to 2030, published by Market Data Centre, The Genomics Market is projected to grow at a solid pace during the forecast period. The presence of key players in the ecosystem has led to a compsetitive and diverse market. The advancement of digital transformation initiatives across multiple industries is expected to drive the worldwide Genomics Market during the study period. This COVID-19 analysis of the report includes COVID-19 IMPACT on the production and, demand, supply chain. This report provides a detailed historical analysis of the global Genomics Market from 2017-to 2021 and provides extensive market forecasts from 2022-to 2030 by region/country and subsectors. The report covers the revenue, sales volume, price, historical growth, and future perspectives in the Genomics Market.

Danaher Corporation found using ticker (DHR) now have 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 363.4 and 265 with the average target price sitting at 328.41. Given that the stocks previous close was at 253.52 this would indicate that there is a potential upside of 29.5%. The day 50 moving average is 252.96 and the 200 day moving average is 286.31. The company has a market capitalisation of $187,622m. Find out more information at: https://www.danaher.com [stock_market_widget type="chart" template="basic" color="green" assets="DHR" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $243,046m based on the market concensus. Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Danaher (DHR) is a Dividend Challenger with 8 consecutive years of dividend growth. DHR shares currently yield 0.39%. See why I am not purchasing DHR stock now.

MINNEAPOLIS, MN / ACCESSWIRE / June 30, 2022 / OneMedNet Corporation ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Imaging Real Word Data, through its proven OneMedNet iRWD solution, today announced the appointment of Dr. Christoph Zindel to its Board of Directors. Dr. Zindel will be officially joining the board by October 1, 2022. Prior to his official appointment, Dr. Zindel agreed to serve on the board on a pro bono basis. Dr. Zindel, a noted industry executive, brings more than 30 years of diagnostic imaging, technology innovation, nuclear medicine and executive leadership experience and joins the board following a distinguished career including as President of Siemens Healthineers AG, where he served as Head of Diagnostic Imaging and served as a Member of the Managing Board at Siemens Healthineers AG. Currently, Dr. Zindel also serves as a Member of the Supervisory Board of Fresenius SE Group, and Senior Vice President, General Manager of Business Line Magnetic Resonance.

Danaher''s (NYSE: DHR ) short percent of float has fallen 7.35% since its last report. The company recently reported that it has 3.99 million shares sold short , which is 0.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com

Pune, July 07, 2022 (GLOBE NEWSWIRE) -- Genomics Market by Vendor Assessment, Technology Assessment, Partner & Customer Ecosystem, type/solution, service, organization size, end-use verticals, and Region – Global Genomics Market Forecast to 2030, published by Market Data Centre, The Genomics Market is projected to grow at a solid pace during the forecast period. The presence of key players in the ecosystem has led to a compsetitive and diverse market. The advancement of digital transformation initiatives across multiple industries is expected to drive the worldwide Genomics Market during the study period. This COVID-19 analysis of the report includes COVID-19 IMPACT on the production and, demand, supply chain. This report provides a detailed historical analysis of the global Genomics Market from 2017-to 2021 and provides extensive market forecasts from 2022-to 2030 by region/country and subsectors. The report covers the revenue, sales volume, price, historical growth, and future perspectives in the Genomics Market.

Danaher Corporation found using ticker (DHR) now have 18 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 363.4 and 265 with the average target price sitting at 328.41. Given that the stocks previous close was at 253.52 this would indicate that there is a potential upside of 29.5%. The day 50 moving average is 252.96 and the 200 day moving average is 286.31. The company has a market capitalisation of $187,622m. Find out more information at: https://www.danaher.com [stock_market_widget type="chart" template="basic" color="green" assets="DHR" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $243,046m based on the market concensus. Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Danaher (DHR) is a Dividend Challenger with 8 consecutive years of dividend growth. DHR shares currently yield 0.39%. See why I am not purchasing DHR stock now.

MINNEAPOLIS, MN / ACCESSWIRE / June 30, 2022 / OneMedNet Corporation ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Imaging Real Word Data, through its proven OneMedNet iRWD solution, today announced the appointment of Dr. Christoph Zindel to its Board of Directors. Dr. Zindel will be officially joining the board by October 1, 2022. Prior to his official appointment, Dr. Zindel agreed to serve on the board on a pro bono basis. Dr. Zindel, a noted industry executive, brings more than 30 years of diagnostic imaging, technology innovation, nuclear medicine and executive leadership experience and joins the board following a distinguished career including as President of Siemens Healthineers AG, where he served as Head of Diagnostic Imaging and served as a Member of the Managing Board at Siemens Healthineers AG. Currently, Dr. Zindel also serves as a Member of the Supervisory Board of Fresenius SE Group, and Senior Vice President, General Manager of Business Line Magnetic Resonance.

Danaher''s (NYSE: DHR ) short percent of float has fallen 7.35% since its last report. The company recently reported that it has 3.99 million shares sold short , which is 0.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com